ECE2023 Poster Presentations Endocrine-related Cancer (62 abstracts)
Impact of vascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study
Francisca Marques Puga 1,2 , Abir Al Ghuzlan 3 , Dana M. Hartl 4 , Mohamed-Amine Bani 3 , Sophie Moog 2 , Fabiana Pani 2 , Ingrid Breuskin 4 , Joanne Guerlain 4 , Matthieu Faron 4 , Desirée Denadreis 5 , Eric Baudin 2 , Julien Hadoux 2 & Livia Lamartina 2
1Centro Hospitalar Universitário do Porto, Department of Endocrinology, Diabetes and Metabolism, Porto, Portugal; 2Gustave Roussy, Département d’Imagerie, Service d’oncologie endocrinienne, Endocrine Oncology Unit, F-94805 Villejuif, France; 3Gustave Roussy, Département de biologie et pathologie médicale, Department of Biology and Pathology, F-94805 Villejuif, France; 4Gustave Roussy, Département Anesthésie Chirurgie et Interventionnel, Department of Anesthesia, Surgery, and Interventional, F-94805 Villejuif, France; 5Gustave Roussy, Département d’Imagerie, Service de Médecine Nucléaire, Nuclear Medicine Unit, F-94805 Villejuif, France
Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.
Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs.
Methods: Retrospective study including patients with otherwise low-risk PTCs but with vascular invasion, diagnosed between 2013 and 2019. The persistence/recurrence during the follow-up was evaluated. Pathology was reviewed to confirm the presence of vascular invasion and determine the type of invasion.
Results: A total of 141 patients were included. Vascular invasion was confirmed in 20.6%. After surgery, 48.9% (n=69) of the patients received radioactive iodine (RAI). The median follow-up time was 4 [3-6] years. Overall, 6 (4.2%) patients experienced persistent/recurrent disease in the neck, including 3 with vascular invasion, confirmed as “only lymphatic”. Overall, patients with tumors harboring vascular invasion had significantly more persistent/recurrence disease compared with those without vascular invasion (10.3% vs 2.7%, P=0.1), especially in the subgroup of patients not treated with RAI (20% vs 1.6%, P=0.049) [OR 15.25, 95% CI 1.24-187.85, P=0.033].
Conclusions: Vascular invasion, including lymphatic invasion only, is associated with a sensibly higher risk of persistent/recurrent disease in otherwise low-risk PTCs, namely in patients not treated with RAI. Lymphatic invasion could have a role in risk-stratification systems for decision making.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more